1-year results from ASPIRE-CD suggest risankizumab (Skyrizi) improves HRQL, well-being, and treatment satisfaction in adults with Crohn's Disease.
Laurie Keefer, PhD
Advertisement
Laurie Keefer, PhD, is a clinical health psychologist and professor of medicine at Icahn School of Medicine at Mount Sinai.
Articles by Laurie Keefer, PhD
Laurie Keefer, PhD, makes the case for integrating mental health, social determinants, and brain-gut behavior therapies into routine GI care.
Keefer emphasizes the importance of treatment satisfaction and health-related quality of life in IBD and reviews findings from ASPIRE-CD.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Highlighting FDA-Approved Therapies in Atopic Dermatitis, With Chris Bunick, MD, PhD
2
Navigating Emotional Burden in IBD
3
Linaclotide in Pediatric IBS-C—Evidence, Indications, and Practical Use
4
Open Communication Between Patients and Providers in IBD
5